LYVE1 antibody (Lymphatic Vessel Endothelial Hyaluronan Receptor 1) (AA 24-227)

Details for Product anti-LYVE1 Antibody No. ABIN115689, Supplier: Log in to see
Antigen
  • LYVE1
  • XLKD1
  • CRSBP-1
  • HAR
  • LYVE-1
  • 1200012G08Rik
  • Crsbp-1
  • Lyve-1
  • Xlkd1
  • lymphatic vessel endothelial hyaluronic acid receptor 1-like
  • lymphatic vessel endothelial hyaluronan receptor 1
  • LOC560618
  • LOC100347960
  • LYVE1
  • Lyve1
Alternatives
anti-Mouse (Murine) LYVE1 antibody for Blocking Reagent
Epitope
AA 24-227
57
28
21
19
18
16
13
11
10
8
7
6
6
4
3
3
1
1
1
1
1
1
1
1
Reactivity
Mouse (Murine)
209
158
41
2
1
1
1
1
1
Host
Rabbit
158
59
58
3
1
1
Clonality
Polyclonal
Conjugate
This LYVE1 antibody is un-conjugated
17
10
10
9
9
9
9
8
6
6
6
6
5
5
5
5
4
4
3
3
3
2
2
1
1
1
1
1
1
1
Application
Enzyme Immunoassay (EIA), Flow Cytometry (FACS), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Western Blotting (WB)
189
121
100
79
51
41
33
28
13
10
2
1
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Available images

Immunogen Highly pure recombinant Mouse soluble LYVE-1 produced in insect cells (Cat.-No DA3524) Remarks: The recombinant soluble LYVE-1 consists of amino acid 24 (Ala) to 228 (Gly) and is fused to a C-terminal His-tag (6xHis).
Specificity Highly specifc for Mouse Lyve-1. No cross reactivities observed so far.
Cross-Reactivity (Details) Species reactivity (tested):Mouse.
Purification Antigen Affinity Chromatography
Alternative Name LYVE-1 (LYVE1 Antibody Abstract)
Background LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41 % similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 Molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 Molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.Synonyms: CRSBP-1, CRSBP1, Cell surface retention sequence-binding protein 1, Extracellular link domain-containing protein 1, HAR, Hyaluronic acid receptor, LYVE1, Lymphatic vessel endothelial hyaluronic acid receptor 1, XLKD1
Gene ID 114332
NCBI Accession NP_444477
UniProt Q8BHC0
Research Area Enzymes
Pathways Glycosaminoglycan Metabolic Process
Application Notes ELISA (1-15 μg/mL). Western blot (1-2 μg/mL). FACS analysis (3-20 μg/mL). Immunohistochemistry on Paraffin and Frozen Sections (0.25-4 μg/mL).
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions For Research Use only
Reconstitution Restore in distilled sterile Water to a concentration of 0.1 - 1.0 mg/mL.
Buffer PBS, pH 7.4, without preservatives or stabilizers
Preservative Without preservative
Handling Advice Avoid repeated freezing and thawing.
Storage 4 °C/-20 °C
Storage Comment The lyophilized IgG is stable at 2-8 °C for one month and at -20 °C for longer. When reconstituted the antibody is stable for at least six weeks at 2-8 °C. For longer store in aliquots at -20 °C.
Supplier Images
Immunohistochemistry (IHC) image for anti-LYVE1 antibody (Lymphatic Vessel Endothelial Hyaluronan Receptor 1) (AA 24-227) (ABIN115689) Paraffin section of mouse intestine stained with ABIN115689
Product cited in: Nakao, Zandi, Faez, Kohno, Hafezi-Moghadam: "Discontinuous LYVE-1 expression in corneal limbal lymphatics: dual function as microvalves and immunological hot spots." in: FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 26, Issue 2, pp. 808-17, 2012 (PubMed).

Heishi, Hosaka, Suzuki, Miyashita, Oike, Takahashi, Nakamura, Arioka, Mitsuda, Takakura, Hojo, Matsumoto, Yamauchi, Ohta, Sonoda, Sato: "Endogenous angiogenesis inhibitor vasohibin1 exhibits broad-spectrum antilymphangiogenic activity and suppresses lymph node metastasis." in: The American journal of pathology, Vol. 176, Issue 4, pp. 1950-8, 2010 (PubMed).

Conrad, Niess, Huss, Huber, von Luettichau, Nelson, Ott, Jauch, Bruns: "Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo." in: Circulation, Vol. 119, Issue 2, pp. 281-9, 2009 (PubMed).

Background publications Jackson: "The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1." in: Trends in cardiovascular medicine, Vol. 13, Issue 1, pp. 1-7, 2003 (PubMed).

Sleeman, Krishnan, Kirkin, Baumann: "Markers for the lymphatic endothelium: in search of the holy grail?" in: Microscopy research and technique, Vol. 55, Issue 2, pp. 61-9, 2001 (PubMed).

Mouta Carreira, Nasser, di Tomaso, Padera, Boucher, Tomarev, Jain: "LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis." in: Cancer research, Vol. 61, Issue 22, pp. 8079-84, 2001 (PubMed).

Mäkinen, Veikkola, Mustjoki, Karpanen, Catimel, Nice, Wise, Mercer, Kowalski, Kerjaschki, Stacker, Achen, Alitalo: "Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3." in: The EMBO journal, Vol. 20, Issue 17, pp. 4762-73, 2001 (PubMed).